These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 15203988)

  • 21. Rational peptide-based tumour vaccine development and T cell monitoring.
    Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
    Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DC-based cancer vaccines.
    Gilboa E
    J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the development of a therapeutic cancer vaccine.
    Avigan D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S2-6. PubMed ID: 16280106
    [No Abstract]   [Full Text] [Related]  

  • 24. Dendritic cell vaccination for cancer therapy.
    Nestle FO
    Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pilot trial of vaccines based on autologous dendritic cells loaded in vitro with tumor antigens in the treatment of cancer of the urinary bladder].
    Shoua AB; Sergienco NF; Sitnikov NV; Chkadua GZ
    Urologiia; 2008; (5):54-7. PubMed ID: 19069498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 27. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell-based cancer vaccination: quo vadis?
    Dauer M; Schnurr M; Eigler A
    Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immune response to breast cancer, and the case for DC immunotherapy.
    Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
    Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reengineering dendritic cell-based anti-cancer vaccines.
    Koski GK; Cohen PA; Roses RE; Xu S; Czerniecki BJ
    Immunol Rev; 2008 Apr; 222():256-76. PubMed ID: 18364007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Migration of dendritic cell based cancer vaccines: in vivo veritas?
    Adema GJ; de Vries IJ; Punt CJ; Figdor CG
    Curr Opin Immunol; 2005 Apr; 17(2):170-4. PubMed ID: 15766677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.